Intellia Therapeutics/NTLA

$33.05

6.54%
-
1D1W1MYTD1YMAX

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.

Ticker

NTLA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Leonard

Employees

526

Headquarters

Cambridge, United States

NTLA Metrics

BasicAdvanced
$2.66B
Market cap
-
P/E ratio
-$5.42
EPS
1.75
Beta
-
Dividend rate

What the Analysts think about NTLA

Analyst Ratings

Majority rating from 28 analysts.
Buy

Price Targets

Average projection from 23 analysts.
112.19% upside
High $144.00
Low $24.00
$33.05
Current price
$70.13
Average price target

NTLA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,329% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$36.2M
204.2%
Net income
$-481.1M
293.7%
Profit margin
-1,329%
29.42%

NTLA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.93%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q1 24
Actual
-$1.17
-$1.40
-$1.38
-
Expected
-$1.40
-$1.32
-$1.50
-$1.38
Surprise
-16.45%
5.99%
-7.93%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Intellia Therapeutics stock

Buy or sell Intellia Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing